logo
home company team portfolio contact
 


November 23, 2011
Radius Closes $27.65 Million Second Tranche of Previously Announced Financing -- more

November 9, 2011
Journal of Petroleum Technology - From Bacteria to Barrels: Microbiology -- more

November 7, 2011
IntraPace: The 'gastric pacemaker' that warns the brain you're full! Could this device retrain the obese to eat more healthily? -- more

November 2, 2011
ExonHit Extends Strategic Collaboration with Allergan -- more

November 1, 2011
Claros Diagnostics - Inc Magazine: Innovation: A Blood Test on a Chip -- more

November 1, 2011
Dicerna Pharmaceuticals Awarded Notice of Allowance by U.S. Patent and Trademark Office for Patent Claims Broadly Covering Dicer Substrate siRNA Molecules -- more

October 21, 2011
Xencor Initiates Phase 1 Study of XmAb®5871 Therapeutic Antibody For the Treatment of Autoimmune Diseases; Dual-Targeted Antibody Aims to Treat Lupus and Rheumatoid Arthritis by Suppressing Autoimmune Response -- more

October 17, 2011
Claros - Runner-Up Medical Devices - Wall Street Journal's 2011 Technology Innovation Awards -- more

October 13, 2011
OPKO Health Announces Acquisition of Claros Diagnostics -- more

October 13, 2011
Enanta Awarded up to $42.7 Million NIAID Contract to Develop a Novel Broad Spectrum Bicyclolide Antibiotic -- more

October 5, 2011
Glori Energy jumps on IPO bandwagon -- more

September 26, 2011
Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch -- more

September 21, 2011
Glori Energy: Oil-loving bugs enhance recovery in old and new reservoirs -- more

September 17, 2011
ExonHit - Brain center to join clinical trial involving Alzheimer's -- more

September 12, 2011
SuperGen, Inc. Changes Name To Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol And New Website -- more

September 12, 2011
superDimension Raises $11 Million in Equity Financing -- more

August 3, 2011
SuperGen Reports 2011 Second Quarter Financial Results -- more

July 25, 2011
Exonhit and BGI announce successful completion of a promising next-generation sequencing project -- more

July 21, 2011
Exonhit and BGI announce successful completion of a promising next-generation sequencing project -- more

July 20, 2011
SuperGen Completes Acquisition of Astex Therapeutics -- more

July 19, 2011
Exonhit announces successful completion of the second phase of EHT Dx14 clinical validation -- more

July 6, 2011
Rib-X Pharmaceuticals and Sanofi Sign a Research Collaboration Agreement on Novel Classes of Antibiotics -- more

July 5, 2011
Glori Energy, a Low-Cost Oil Recovery Company, Receives Boost from Energy Technology Ventures—a GE-NRG Energy-ConocoPhillips Venture -- more

June 29, 2011
Luca Technologies Files Registration Statement for Initial Public Offering -- more

May 26, 2011
Tragara Pharmaceuticals’ Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis -- more

May 24, 2011
Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study -- more

May 24, 2011
Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis -- more

May 9, 2011
New Studies Support CardioFocus HeartLight™ Endoscopic Ablation System's Notable Treatment Results for Paroxysmal Atrial Fibrillation -- more

May 3, 2011
Astex wins £5.9m GSK milestone windfall -- more

April 12, 2011
Ensemble Therapeutics Achieves Milstone in Bristol-Myers Squibb Collaboration -- more

April 9, 2011
Cambrios Provides ClearOhm Film for Smartphones -- more

April 6, 2011
SuperGen and Astex Therapeutics Enter Definitive Merger Agreement -- more

April 4, 2011
ExonHit announces publication of EHT 0202 Phase IIa results in Current Alzheimer Research -- more

April 4, 2011
superDimension Receives FDA 510(k) Clearance for Marker Delivery Kit -- more

April 4, 2011
Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C -- more

March 30, 2011
Cambrios: Nissha Started Mass Production of Touch Sensor Films Using Metal Nanowires -- more

March 29, 2011
ExonHit announces successful completion of the first phase of EHT Dx14 ongoing clinical validation -- more

March 15, 2011
ExonHit Therapeutics reports 2010 results -- more

March 15, 2011
ExonHit announces CE marking of AclarusDx™ -- more

March 4, 2011
IntraPace: Stomach pacemaker could help obese lose weight -- more

March 1, 2011
VaxInnate Awarded Contract by the U.S. Government To Develop Recombinant Seasonal and Pandemic Flu Vaccines -- more

February 28, 2011
VaxInnate: HHS awards contracts to develop new flu vaccine technology -- more

February 16, 2011
Astellas and AVEO Pharmaceuticals Enter into Worldwide Agreement to Develop and Commercialize Tivozanib Outside of Asia -- more

February 10, 2011
Rib-X Initiates Antibiotic Drug Trial -- more

February 1, 2011
Astex Receives Milestone from Wellcome Trust for Pioneering HCV Research -- more

January 11, 2011
IntraPace Receives CE Mark Certification for the abiliti® System for the Treatment of Obesity -- more

January 6, 2011
Amgen And Xencor Enter Option Deal To Co-develop Xencor's Novel Antibody For Autoimmune Diseases -- more

December 27, 2010
Technology Review: The Year's Best Tech Products (Claros Diagnostics) -- more

December 10, 2010
AVEO's Tivozanib in Combination with Paclitaxel Demonstrates Safety in Patients with Metastatic Breast Cancer; Data Presented at San Antonio Breast Cancer Symposium -- more

December 9, 2010
Asterand to settle final payment for BioSeek acquisition with cash -- more

December 7, 2010
Dicerna Pharmaceuticals and Kyowa Hakko Kirin Expand Dicer Substrate Technology Partnership into Immunologic and Inflammatory Diseases -- more

December 1, 2010
Encouraging Data on Astexs' Anti-Cancer Drug AT9283 to be Presented at ASH -- more

December 1, 2010
OSI Pharmaceuticals, Inc. Exercises Option under Discovery and Translational Research Collaboration with AVEO -- more

November 18, 2010
AVEO's Tivozanib in Combination with FOLFOX6 Demonstrates Anti-tumor Activity and Safety in Advanced GI Cancers; Results Presented at EORTC-NCI-AACR Symposium -- more

November 16, 2010
AVEO Pharmaceuticals Initiates Patient Enrollment in Phase 1b Tivozanib Combination Trial in Advanced Solid Tumors -- more

November 11, 2010
Encouraging Data from Phase I Studies of Astex's Anti-Cancer Drugs AT7519, AT9283 and AT13387 to be Presented at EORTC-NCI-AACR Annual Meeting -- more




November 8, 2010
ExonHit presents promising data on genomic biomarkers in Alzheimer's disease clinical trials -- more

November 4, 2010
Astex and the NCIC Clinical Trials Group Announce Start of Phase II Clinical Study of AT9283 in Multiple Myeloma -- more

November 2, 2010
VaxInnate's Novel Recombinant Flu Vaccine Named a Top 10 Biopharma Project to Watch in 2011 -- more

November 1, 2010
Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/R for Treatment of Hepatitis C -- more

October 28, 2010
Coherex Medical Expands Portfolio with New Medical Device; New Heart Implant Treats Patients at Risk for Stroke -- more

October 25, 2010
Milestone Transition in Astex Alzheimer's Disease Collaboration with AstraZeneca -- more

October 21, 2010
Dicerna Pharmaceuticals Announces Second Close of Series B Financing -- more

October 1, 2010
National Cancer Institute awards contract to Asterand, valued at up to $24.3 million -- more

September 23, 2010
Asterand's Subsidiary BioSeek Signs Agreement with Cellzome -- more

September 22, 2010
Dalia Cohen Ph.D. Joins Asterand as Chief Scientific Officer -- more

September 20, 2010
Targeson Inc. appoints Origin Biosciences Inc. as Chinese Distributor -- more

September 16, 2010
ExonHit Therapeutics ' Strong growth of half-year 2010 results -- more

September 15, 2010
Dicerna Pharmaceuticals Named One of the 'Fierce 15' Leading Biotech Companies of 2010 -- more

September 13, 2010
Targeson, Inc. appoints Kingyoup Enterprises Co., Ltd. as Taiwan Distributor -- more

September 9, 2010
Tragara Pharmaceuticals Initiates Phase I Clinical Program for TG02 -- more

September 7, 2010
superDimension Raises $24.8 Million in Debt and Equity Financing -- more

August 26, 2010
Energy Grasses Take Center Stage at Ceres Field Day -- more

August 13, 2010
Santhera Obtains European Patent for Use of Catena'/Sovrima' in the Treatment of Muscular Dystrophies -- more

August 12, 2010
Trubion Pharmaceuticals Announces Agreement to be Acquired by Emergent BioSolutions -- more

August 12, 2010
Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma -- more

August 11, 2010
Dicerna Closes $25 Million Series B Financing -- more

July 29, 2010
Astex scientists describe novel HSP90 inhibitors in two key publications in Journal of Medicinal Chemistry -- more

July 19, 2010
GE Capital Provides $5 Million Credit Facility To Mitralign, Inc. -- more

July 19, 2010
VaxInnate: Two Start-Ups Aim To Change Economics Of Vaccine Production -- more

July 13, 2010
Fairfield County resident, Cornelius T. Ryan, named one of the 'Irish Life Science 50' -- more

June 28, 2010
MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program -- more

June 25, 2010
Gilead Sciences to Acquire CGI Pharmaceuticals for Up to $120 Million -- more

June 16, 2010
Santhera's Catena' Improved Vision in Patients with Leber's Hereditary Optic Neuropathy; Regulatory Submissions Planned in First Half of 2011 -- more

June 16, 2010
AVEO Pharmaceuticals Granted Patents for Diagnostic Tests to Identify Patient Populations Likely to Respond to Tivozanib Treatment -- more

June 14, 2010
ExonHit signs an exclusive agreement with Genmab for novel splice variant targets in breast cancer -- more

June 14, 2010
BRAINCELLS INC. Announces Results from Exploratory Phase 2A Trial of BCI-540 in Depression with Anxiety -- more

June 14, 2010
Asterand Signs Agreement with Amylin Pharmaceuticals -- more

June 9, 2010
ExonHit discloses the final terms of the acquisition of RedPath Integrated Pathology -- more

June 7, 2010
EPA Extends Asterand's Role in ToxCast ' Program -- more

June 5, 2010
AVEO Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating SCH 900105 (AV-299) in Non-Small Cell Lung Cancer -- more

May 20, 2010
Novozymes and Ceres partner on biofuel crops -- more

May 18, 2010
Scientists Weigh Use of Bacteria for Cleaner Fossil Fuel Production -- more

April 29, 2010
BrainCells Issued First U.S. Patent for Drug Combinations that Modulate Neurogenesis -- more

April 27, 2010
VaxInnate's VAX125 Seasonal Flu Vaccine Shown Safe and Highly Immunogenic in Phase II Study of Elderly Subjects -- more

April 26, 2010
ExonHit to acquire RedPath Integrated Pathology, Inc. and accelerate growth in molecular diagnostics -- more

April 22, 2010
Cardiofocus Secures $5M in Financing -- more

April 22, 2010
Asterand Sponsors Inaugural Human Tissue Conference -- more

April 14, 2010
AVEO Pharmaceuticals Receives Milestone Payment from Biogen Idec under Licensing Agreement for ErbB3 Antibody Program -- more

April 13, 2010
Encouraging data from three Astex collaborative programmes to be presented at the 101st American Association for Cancer Research (AACR) Annual Meeting 2010 -- more

April 6, 2010
ExonHit receives "Innovative Company" accreditation from the French state innovation agency OSEO -- more

March 31, 2010
Claros: Prostate Cancer Results While You Wait -- more

March 31, 2010
superDimension: iLogic Video Footage -- more

March 30, 2010
Dicerna Pharmaceuticals and Ipsen Enter into an Exclusive Research Collaboration for the Development of New Therapeutic Agents in Endocrinology and Oncology -- more

March 29, 2010
Multiple Myeloma Research Foundation (MMRF) Grants $1.0 Million Each to Intellikine, Inc. and Tragara Pharmaceuticals, Inc. to Advance Next-Generation Therapies for Multiple Myeloma -- more

March 29, 2010
ExonHit presents new data on its Alzheimer's lead candidate at the International Geneva/Springfield Symposium -- more

March 23, 2010
Rib-X Appoints Mark Leuchtenberger As President And CEO -- more

March 22, 2010
Molecular Biometrics Receives Frost & Sullivan Technology Innovation Award -- more

March 19, 2010
Dr. Thomas Hofstaetter Named President and CEO of VaxInnate; Dr. Alan Shaw Assumes New Role as Chief Scientific Officer and Chairman of the Board -- more

March 11, 2010
AVEO Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering -- more

March 3, 2010
ExonHit reports out-licensing of EHT/AGN 0001 -- more

March 3, 2010
Molecular Biometrics Announces Launch of Viametrics-E' -- more

March 2, 2010
Abbott and Enanta Announce Advancement of Hepatitis C Collaboration-- Initiation of Phase 2 Clinical Trial Investigating Three Individual HCV Antivirals -- more

March 2, 2010
Enanta Nominates EDP-239 as Lead Development Candidate for NS5A HCV Inhibitor Program -- more

February 23, 2010
ExonHit announces the inclusion of proprietary lead compounds into Allergan collaboration -- more

February 11, 2010
ExonHit chosen to join the European Innovative Medicines Initiative consortium on Alzheimer's disease -- more

February 9, 2010
Astex Executive Receives the AstraZeneca Business Development Professional of the Year 2009 Award -- more

February 8, 2010
Tragara Raises $5M -- more

January 12, 2010
Molecular Biometrics Closes $12.5 Million Series B Equity Funding -- more

January 6, 2010
Ensemble Discovery Initiates Collaboration with Pfizer to Develop Novel Drugs Against Protein-Protein Interaction Targets -- more

January 5, 2010
Circulite' closes on Series C Financing -- more

January 4, 2010
Dicerna Signs Research Collaboration and License Agreement for Drug Delivery Systems and Dicer Substrate siRNA (DsiRNA) Pharmaceuticals with Kyowa Hakko Kirin -- more

December 11, 2009
Astex Wins Company Newsflow of the Year Award -- more

December 9, 2009
Former Wyeth Executive Joins VaxInnate as Chief Operating Officer -- more

December 8, 2009
HydroCision Introduces a New Low Profile Device For Minimally Invasive Endoscopic Discectomy Market -- more

December 7, 2009
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board -- more

November 23, 2009
Asterand Announces Extension of Agreement with Bristol-Myers Squibb -- more

November 12, 2009
Astex Announces Strategic Drug Discovery Alliance with GlaxoSmithKline -- more

November 9, 2009
Astex to disclose the structure of its HSP90 inhibitor, AT13387, at the AACR-NCI-EORTC Annual Meeting 2009 -- more

November 3, 2009
Santhera Receives Grant from Association Fran'aise contre les Myopathies for its Omigapil Program in Congenital Muscular Dystrophy -- more

November 3, 2009
Astex Announces a CRADA with the National Cancer Institute for its HSP90 inhibitor AT13387 -- more

November 2, 2009
Lung Cancer Diagnosis Breakthrough from superDimension Receives Category I' CPT Reimbursement Codes -- more

November 2, 2009
superDimension Launches Second Generation iLogic'Electromagnetic Navigation Bronchoscopy System to Detect and Diagnose Lung Cancer -- more

November 2, 2009
ExonHit will participate in the MAPT study for the prevention of cognitive decline in old people -- more

November 2, 2009
superDimension, Inc.: Company Expects Broadened Physician Adoption for Minimally Invasive Technology That Offers Potential to Change Standard of Care -- more

October 30, 2009
ExonHit presents new clinical advances on its Alzheimer's diagnostic and therapeutic programs -- more

October 20, 2009
BrainCells Inc. Broadens Scientific Advisory Board Adding Drs. Edward Scolnick and David Holtzman -- more

October 7, 2009
Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry -- more

September 22, 2009
Coherex Medical Signs Exclusive Distribution Agreement with Abbott -- more

September 18, 2009
Mount Sinai First In Nation to Ablate Atrial Fibrillation Using New Visually-Guided Balloon Catheter -- more

September 16, 2009
AVEO Pharmaceuticals Appoints William J. Slichenmyer, M.D., Sc.M., as Chief Medical Officer and Robert C. Young, M.D., to Board of Directors -- more

September 9, 2009
NeuroInvestment : BrainCells and Neurogenesis: Proof of Principle and More -- more

September 9, 2009
Luca Technologies Named a Global Cleantech 100 Clean Technology Company by the Guardian and Cleantech Grouptm -- more

September 9, 2009
NeuroInvestment: Company Spotlight - BrainCells Inc. -- more

August 20, 2009
Coherex Medical Closes $16.5 Million Series B Preferred Stock Financing -- more

August 5, 2009
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis -- more

July 29, 2009
Pathway PV Atherectomy System: The Best Designs of 2009 - Business Week -- more

July 27, 2009
Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression -- more

July 21, 2009
OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration -- more

July 20, 2009
Asterand Signs Global Agreement with Lundbeck Giving Access to its Human Tissue Samples and Drug Discovery Services -- more

July 8, 2009
Dicerna Pharmaceuticals Announces Appointment of Industry Veteran David Madden as Chairman of the Board -- more

July 7, 2009
CardioFocus Receives CE Mark for Atrial Fibrillation Ablation Catheter -- more

June 26, 2009
Santhera Enters Agreement with Columbia University to Investigate Additional Potential of Catena' in MELAS -- more

June 24, 2009
Santhera and NIH Collaborate To Evaluate Catena' in Primary Progressive Multiple Sclerosis -- more

June 22, 2009
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration -- more

June 1, 2009
Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL) -- more

May 29, 2009
AV-951 Demonstrates Prolonged Progression-Free Survival and Excellent Safety Profile in Patients with Advanced Kidney Cancer -- more

May 27, 2009
ExonHit and Institut Gustave Roussy Announce the Signing of a License Agreement for Novel Breast Cancer Diagnostic Assay -- more

May 21, 2009
Pathway Medical Technologies Closes $42.5M Series D Financing; Announces New Investment From WRF -- more

May 20, 2009
Ceres Yield Results: Energy Crop Benefits are Greatly Underestimated -- more

May 19, 2009
Elixir Pharmaceuticals Signs Option Agreement with a Major Pharmaceutical Company; Completes $12M Equity Financing -- more

May 10, 2009
ZettaCore Raises $21M; Panasonic Makes Strategic Investment -- more

May 6, 2009
VaxInnate Corporation Closes $30 Million Round of Financing; Wellcome Trust Leads Round -- more

May 5, 2009
Forbes Magazine - VaxInnate: The Flu Vaccine Accelerator -- more

April 30, 2009
Nfocus Neuromedical Elects Eric P. Milledge Chairman of Board -- more

April 30, 2009
Nfocus Neuromedical Appoints Robert O'Holla to Head Regulatory -- more

April 27, 2009
VaxInnate's Seasonal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Study -- more

April 23, 2009
Asterand Announces Collaborative Agreement to Characterise Antibodies -- more

April 14, 2009
Astex Presents Key Data Differentiating its Phase I HSP90 inhibitor, AT13387, at the AACR Annual Meeting 2009 -- more

April 14, 2009
Astex Reports Positive Clinical Biomarker Data from its Phase I study on CDK Inhibitor AT7519 at the AACR Annual Meeting 2009 -- more

April 13, 2009
High-Yielding Switchgrass the Focus of Ceres and University of Georgia Researchers -- more

April 8, 2009
Merck & Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation -- more

April 2, 2009
Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009 -- more

March 31, 2009
Astex Achieves Milestones in Drug Discovery Collaboration -- more

March 30, 2009
BrainCells Inc. Appoints Philip Jochelson, M.D. Chief Medical Officer and Jason Levin Chief Business Officer -- more

March 30, 2009
CircuLite Demonstrates Long-Term Improvements and Hemodynamic Benefits with Synergy' Partial Circulatory Support in Chronic Heart Failure Patients -- more

March 24, 2009
Astex Awarded '2 Million from Wellcome Trust for Pioneering HCV Research -- more

March 24, 2009
Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes -- more

March 24, 2009
AVEO and Biogen Idec Form Strategic Alliance for Development and Commercialization of ErbB3-Targeted Antibodies -- more

March 18, 2009
BrainCells Inc. Selected to Present at InsideVenture's Debut Investor Conference - March 25-26, Santa Barbara, California -- more

March 13, 2009
Wide-Ranging Restructuring Bears Fruit for Asterand -- more

March 12, 2009
Claros Diagnostics Inc: Innovation in Tough Times -- more

March 11, 2009
CircuLite' Completes Initial Close on $33 Million Series C Financing Plan and Appoints Chief Medical Officer -- more

March 10, 2009
AVEO Initiates Phase 1b/2a Clinical Trial of Novel, Triple VEGF Receptor Inhibitor AV-951 in Non-Small Cell Lung Cancer -- more

March 9, 2009
Seahorse Bioscience, Inc. acquires BioProcessors Corp. -- more

March 6, 2009
Antisoma: Well-funded, late-stage M&A target -- more

March 2, 2009
Xencor and Pfizer enter into Antibody Technology Licensing Agreement -- more

March 2, 2009
Astex Receives Award from the Multiple Myeloma Research Foundation to Support Clinical Development of AT7519 -- more

February 26, 2009
ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, Its Phase II Drug for Alzheimer's Disease -- more

February 23, 2009
Xencor and CSL Limited Establish Antibody Optimization Collaboration -- more

February 11, 2009
Astex and Cancer Research UK Collaborate on Clinical Studies of AT9283 in Childhood Cancers -- more

January 29, 2009
Concentric Medical Expands Product Offering in Neuro Access -- more

January 26, 2009
Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing -- more

January 26, 2009
Concentric Medical Reaches Important Stroke Milestone -- more

January 21, 2009
S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317 -- more

January 12, 2009
AngioDynamics Acquires FlowMedica Benephit(R) Renal Therapy Product Line -- more

January 8, 2009
Concentric Medical Closes on $15 Million Financing -- more

December 11, 2008
Ceres: First Seed Sales of Dedicated Energy Crops Begin -- more

December 11, 2008
Santhera Enrolls Last Patient in European Phase III Trial Evaluating SNT-MC17/Idebenone in Friedreich's Ataxia -- more

December 8, 2008
Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin -- more

December 2, 2008
BrainCells Inc. Appoints David E. Thompson to its Board of Directors -- more

November 20, 2008
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million -- more

November 7, 2008
Santhera Presents Preclinical Data on Oral MC4 Receptor Antagonists for Treatment of Cancer Cachexia at AICR Research Conference -- more

November 6, 2008
Santhera Raises CHF 15.9 Million in Private Placement with Strategic Investor Ares Life Sciences -- more

October 31, 2008
Critical Therapeutics, Inc. Announces Stockholder Approvals Related to Merger with Cornerstone BioPharma Holdings, Inc. and 10-to-1 Reverse Stock Split -- more

October 31, 2008
Santhera Enrolls Last Patient in Pivotal US Phase III with SNT-MC17/Idebenone in Friedreich's Ataxia -- more

October 27, 2008
Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis -- more

October 26, 2008
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC / IDSA Joint Meeting -- more

October 20, 2008
Concentric Medical Launches Distal Access Catheter -- more

October 16, 2008
BrainCells Inc: Salk Scientist Fred H. Gage To Receive The Keio Medical Science Prize -- more

October 14, 2008
Astex presents updates on AT13387, its HSP90 Inhibitor, and AT9283, its Multi-Targeted Kinase Inhibitor at the EORTC-NCI-AACR Cancer Conference -- more

October 10, 2008
Santhera Launches CATENA' in Canada -- more

September 29, 2008
Cancer Research UK and Astex Therapeutics Join Forces to Develop New Anti-Cancer Treatment -- more

September 25, 2008
Publication in European Heart Journal Highlights Potential of Santhera's SNT-MC17/Idebenone in Duchenne Muscular Dystrophy -- more

September 23, 2008
AVEO Pharmaceuticals Initiates First Clinical Trial of Novel HGF Antagonist in Patients with Advanced Solid Tumors and Lymphomas -- more

September 23, 2008
Concentric Medical to Sponsor Randomized Trial -- more

September 17, 2008
Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program -- more

September 15, 2008
Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic with Activity Against Hospital- and Community-Acquired MRSA -- more

September 9, 2008
Ceres Trials Energy Crops at Georgia Biofuel Facility -- more

September 5, 2008
Pathway Medical Technologies Receives FDA Clearance for JetstreamTM Pathway PVTM Atherectomy System -- more

August 27, 2008
Asterand to Enter Into Exclusive License Agreement with Allergan for Pre-Clinical Compounds Focused on Diseases of the Eye -- more

August 25, 2008
AVEO Initiates Phase 1b Combination Trial of AV-951 with FOLFOX6 in Patients with Advanced Colorectal and Other Gastrointestinal Cancers -- more

August 22, 2008
Santhera's 2008 Interim Results Reflect Advances in Clinical Development and Preparation for First Product Launch -- more

August 21, 2008
VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study -- more

August 15, 2008
Santhera's Omigapil Receives Orphan Drug Designation from FDA and EMEA -- more

August 11, 2008
Cardiome and Astellas Announce Receipt of FDA Approvable Letter for KYNAPID -- more

August 8, 2008
Santhera Provides Update on Clinical/Regulatory Processes with SNT-MC17/Idebenone for the Treatment of Friedreich's Ataxia -- more

July 30, 2008
Memory Pharmaceuticals Presents Positive Preclinical Data for MEM 68626 at ICAD 2008 -- more

July 24, 2008
Santhera Receives First Product Approval: Health Canada Approves Catena' for Treatment of Friedreich's Ataxia -- more

July 15, 2008
Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 in Complicated Skin and Skin Structure Infections -- more

July 14, 2008
Cardiome Announces Positive Phase 2b Results for Oral Vernakalant -- more

June 18, 2008
Elixir Pharmaceuticals Announces Ghrelin Agonist Data Presentation at the Endocrine Society Annual Meeting -- more

June 16, 2008
Critical Therapeutics Announces Stock Listing Transfer From NASDAQ Global Market to NASDAQ Capital Market -- more

June 11, 2008
llumina Announces Participation in the 1000 Genomes Project -- more

June 9, 2008
Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V. -- more

June 9, 2008
Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions -- more

June 4, 2008
Loic Maurel Joins ExonHit Therapeutics to Become CEO -- more

June 2, 2008
Trubion Announces Presentation of Positive TRU-016 Data at ASCO -- more

June 2, 2008
Critical Therapeutics Completes Phase II Clinical Trial for Zileuton Injection -- more

May 29, 2008
AVEO Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of AV-951 in Patients with Metastatic Renal Cell -- more

May 28, 2008
Elixir Pharmaceuticals Researchers Publish New Data Validating Ghrelin as a Key Metabolic Regulator -- more

May 20, 2008
Dynogen Presents Results of Its Positive Phase 2a IBS-c Study with DDP733 -- more

May 2, 2008
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals' Nicotinic Alpha-7 Agonist, MEM 3454 -- more

May 1, 2008
Critical Therapeutics Signs Definitive Agreement to Merge with Cornerstone BioPharma -- more

April 30, 2008
Dynogen to Present Positive Clinical Data For DDP225 And DDP733 At Digestive -- more

April 28, 2008
Elixir Pharmaceuticals Announces Issuance of SIRT Patent Covering Development of New Therapies Based on Breakthrough Science -- more

April 21, 2008
Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis -- more

April 21, 2008
Santhera Shareholders Approve all Board Proposals at Annual Shareholders' Meeting --
June 6, 2007
Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts -- more

April 3, 2007
Lilly Announces Completion of Hypnion Acquisition -- more

January 26, 2007
Illumina Announces the Completion of Its Acquisition of Solexa -- more

more

April 17, 2008
BrainCells Inc. Expands Series B Financing to $50 Million -- more

April 16, 2008
Xanthus' Symadex Reverses Disease in Preclinical Mouse Models of Multiple Sclerosis -- more

April 15, 2008
Pathway Medical Technologies, Inc. Secures $24.5 Million Financing -- more

April 15, 2008
Xanthus Presents Data Supporting Distinctive Mechanism of Action for Xanafide' -- more

April 11, 2008
Santhera Presents Clinical Efficacy Data of SNT-MC17 in DMD at the American Academy of Neurology Annual Meeting -- more

April 10, 2008
Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA -- more

April 2, 2008
Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis -- more

March 31, 2008
ExonHit Appoints a New Management Board -- more

March 27, 2008
Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update -- more

March 25, 2008
Elixir Announces Completion of Enrollment in Pivotal Phase III Clinical Trial for New Diabetes Drug -- more

March 10, 2008
BrainCells Inc. Completes $30 Million Initial Closing of Series B Financing -- more

February 29, 2008
February 29, 2008: Santhera Reports Financial Results and Significant Operational Progress for 2007 -- more

February 7, 2008
Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer -- more

February 6, 2008
Astex Receives IND Approval for its Small Molecule HSP90 Inhibitor AT13387; Astex Announces Extension of Drug Discovery Alliance -- more

February 6, 2008
Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive Merger Agreement -- more

February 4, 2008
Mitralign Successfully Completes First Human Case -- more

January 31, 2008
AVEO Initiates Phase 1b Combination Clinical Trial of Novel Triple VEGF Receptor Inhibitor AV-951 in Metastatic Renal Cell Carcinoma -- more

January 30, 2008
Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes 'CTA Acceptance in the Netherlands Triggers Milestone Payment to Eisai -- more

January 22, 2008
Xanthus Announces Oral Fludarabine NDA Accepted for Review by U.S. FDA -- more

January 3, 2008
AVEO Pharmaceuticals Appoints Kenneth M. Bate to Board of Directors -- more

December 14, 2007
ACADIA Pharmaceuticals Announces Completion of Enrollment of ACP-104 Phase IIb Clinical Trial Ahead of Schedule -- more

December 10, 2007
Critical Therapeutics Receives $5.0 Million Milestone Payment from DEY for Commercial Launch of ZYFLO CR -- more

December 4, 2007
AVEO Pharmaceuticals and Lilly Sign Collaboration for Clinical Drug Response Project -- more

December 4, 2007
Coherex Medical Hires Top Medical Industry Veteran to Fill Global Market Development Seat -- more

December 3, 2007
Mitralign Announces Closing of Series C Financing -- more

November 29, 2007
Health Canada Accepts Santhera's Submission for Marketing Authorization of SNT-MC17 in Friedreich's Ataxia -- more

November 14, 2007
Dicerna, Startup Based on RNAi Biology, Licenses IP from City of Hope and Closes $13 Million Series A Financing -- more

November 12, 2007
Santhera Showcases Potential and Progress of its Clinical Development Pipeline -- more

November 9, 2007
Santhera Starts Phase IIb Clinical Trial with JP-1730 in Dyskinesia in Parkinson's Disease --
December 29, 2006
Merck & Co., Inc. Announces Completion of Acquisition of Sirna Therapeutics, Inc. -- more

October 18, 2006
Trubion Pharmaceuticals Announces Initial Public Offering -- more

more

November 8, 2007
ExonHit Completes a Prototype to Detect Alzheimer's Disease from Blood -- more

November 6, 2007
Results from Phase 1 Study of AVEO's Novel Triple VEGF Receptor Inhibitor AV-951 Show 100% of Renal Cell Cancer Patients Achieved Partial Response or Stable Disease -- more

November 2, 2007
Memory Pharmaceuticals Announces Positive Phase 2a Results for MEM 3454 in Alzheimer's Disease -- more

November 1, 2007
AVEO Pharmaceuticals Appoints David Johnston as Chief Financial Officer -- more

November 1, 2007
Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies -- more

October 29, 2007
Santhera Reports Encouraging, First Data from Phase IIa Clinical Trial with SNT-MC17 in Duchenne Muscular Dystrophy -- more

October 25, 2007
Elixir Pharmaceuticals Names Paul M. Martha, M.D. as Chief Medical Officer -- more

October 24, 2007
Santhera's CSO Thomas Meier Receives BioValley Award for Scientific and Entrepreneurial Merits -- more

October 15, 2007
Dynogen's Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1B Study -- more

October 15, 2007
Critical Therapeutics Announces Enrollment in Phase III Trial of Zileuton in Patients with Acute Exacerbations of COPD -- more

October 10, 2007
Critical Therapeutics Announces the Issuance of Four New Patents for Its Alpha-7 and HMGB1 Preclincial Programs -- more

October 8, 2007
Xanthus Initiates Pivotal Phase 3 Trial of Xanafide in Secondary Acute Myeloid Leukemia -- more

October 8, 2007
Critical Therapeutics and Dey, L.P. Launch Perforomist(TM) (Formoterol Fumarate) Inhalation Solution -- more

October 4, 2007
Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia -- more

October 3, 2007
Coherex Medical, Inc., a privately held medical device company,today announced it has successfully completed the first human cases of its Coherex FlatStent(TM) PFO Closure System -- more

October 2, 2007
AVEO Pharmaceuticals to Utilize Peptech's Breakthrough Technology to 'Humanise' Internal Drug Candidates -- more

October 2, 2007
OSI Pharmaceuticals and AVEO Pharmaceuticals Enter into an Oncology Drug Discovery and Translational Research Collaboration -- more

October 1, 2007
Critical Therapeutics Initiates Phase I Clinical Trial of the R(+) Isomer of Zileuton -- more

September 28, 2007
Santhera Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich's Ataxia and Provides Details on Study Design -- more

September 27, 2007
Ceres Raises $75 Million in Late-Stage Financing -- more

September 27, 2007
BrainCells Inc., Taisho Pharmaceutical Co., Ltd. Sign Licensing Agreement for Novel CNS Program -- more

September 27, 2007
Critical Therapeutics and Dey Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets -- more

September 25, 2007
Critical Therapeutics Highlights Near-Term Milestones to Drive Commercial Success and Clinical Development -- more

September 24, 2007
Elixir Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering -- more

September 21, 2007
Santhera to Seek Canadian Market Approval for SNT-MC17 in Friedreich's Ataxia -- more

September 17, 2007
Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis -- more

September 13, 2007
Xanthus' Xanafide is Unaffected by Multi-Drug Resistance in In Vitro Preclinical Studies in Leukemia Cells -- more

September 13, 2007
Critical Therapeutics Announces Publication of Results from Two Asthma Studies -- more

September 10, 2007
Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis -- more

September 7, 2007
Publication in LANCET Neurology Highlights Potential of Santhera's SNT-MC17 for Friedreich's Ataxia -- more

August 29, 2007
Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908 -- more

August 29, 2007
FlowMedica Announces Completion of the Benephit System Renal Infusion Therapy (Be-RITe) Registry -- more

August 28, 2007
Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials -- more

August 17, 2007
Concentric Medical, Inc. Files Registration Statement for Proposed Initial Public Offering -- more

August 17, 2007
Santhera's 2007 Interim Results Reflect Increased Investment in Advanced Development Pipeline -- more

August 16, 2007
European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreich's Ataxia by Santhera -- more

August 6, 2007
BioProcessors Raises $10 Million -- more

August 2, 2007
Santhera and Takeda Extend European Marketing Collaboration for SNT-MC17 into Duchenne Muscular Dystrophy -- more

July 26, 2007
Elixir Pharmaceuticals to Present Data from Programs to Treat and Prevent Metabolic Diseases -- more

July 16, 2007
Intechra Adds National Logistics Network, Two Acquisitions -- more

July 12, 2007
Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 3454 Alzheimer's Disease Trial -- more

July 10, 2007
Critical Therapeutics Initiates Phase IV Study Evaluating ZYFLO CR(TM) in Asthma Patients on Inhaled Corticosteroids Whose Symptoms Are Poorly Controlled -- more

July 2, 2007
Santhera Licenses Omigapil for Treatment of Rare Neuromuscular Diseases -- more

June 26, 2007
Critical Therapeutics' Zileuton Provides Additional Asthma Control When Combined with Inhaled Corticosteroids -- more

June 26, 2007
ACADIA Pharmaceuticals Initiates Phase IIb Clinical Trial with ACP-104 in Patients with Schizophrenia -- more

June 25, 2007
Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Association's Annual Meeting -- more

June 25, 2007
Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast(R) to Maintain Glycemic Control in Patients with Type 2 Diabetes -- more

June 19, 2007
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -- more

June 18, 2007
AVEO Pharmaceuticals' CEO Tuan Ha-Ngoc Receives Ernst & Young New England Entrepreneur of the Year' Award -- more

June 12, 2007
Xanthus Completes Special Protocol Assessment with FDA for Phase 3 Registration Trial of Xanafide in Patients with Secondary Acute Myeloid Leukemia -- more

June 12, 2007
Critical Therapeutics Announces the Publication of Data for ZYFLO CR(TM) (Zileuton) Extended-Release Tablets in the Journal of Asthma -- more

June 11, 2007
ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis -- more

June 7, 2007
Agilent Technologies Adds Strength to Its Life Science Business with Acquisition of Stratagene -- more

June 7, 2007
Dynogen Reports Positive Results in Phase 1B GERD Study -- more

June 4, 2007
Cardiome and Astellas Announce Positive Results from ACT 2 Trial -- more

June 3, 2007
Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer -- more

June 2, 2007
Xanthus Presents Phase 2 Data Showing Xanafide is Associated with Complete Remissions in Secondary AML -- more

May 31, 2007
FDA Approves Critical Therapeutics' Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for Asthma -- more

May 22, 2007
Intechra Secures Additional $30 Million in Equity Capital -- more

May 15, 2007
Solstice Neurosciences, Inc. Announces Commercialization Agreement -- more

May 14, 2007
Critical Therapeutics' Sales Force Gains Access to a Second Product as FDA Approves Co-Promotion Partner's New Treatment for COPD -- more

May 3, 2007
Xanthus Presents Novel Approach for Autoimmune Disease Reversal with Symadex -- more

May 3, 2007
AVEO Pharmaceuticals Closes $53 Million in Series D Funding -- more

May 2, 2007
Critical Therapeutics' Co-Promotion Partner, DEY, L.P., Launches U.S. Sales and Marketing of ZYFLO(R) for Asthma -- more

April 23, 2007
CircuLite Closes an Additional $5M in Series B Private Placement Funding -- more

April 11, 2007
Xanthus Acquires from Johns Hopkins University Exclusive License to Patent Estate Covering FLT3 Pathway as a Target for Treating Autoimmune Diseases -- more

April 6, 2007
Stratagene Signs Definitive Agreement to Be Acquired by Agilent Technologies -- more

April 5, 2007
Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 1003 Alzheimer's Disease Trial -- more

April 4, 2007
AVEO enters into Worldwide License and Development Agreement with Schering-Plough for AV-299, AVEO's Novel Anti-HGF Antibody -- more

April 4, 2007
ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering -- more

April 2, 2007
Radius Raises $57.5 Million in Second Private Financing Round -- more

April 2, 2007
Nfocus Neuromedical Inc. Raises over $20 Million in Series B Financing -- more

March 28, 2007
Santhera Announces Appointment of Cesare Mondadori as Head of Research -- more

March 27, 2007
BrainCells and Lundbeck Form CNS Drug Research Collaboration -- more

March 22, 2007
Xanthus Initiates a Phase 1 Study of Clomet for Treatment of Solid Tumors -- more

March 20, 2007
Radius Begins Phase II Clinical Trial of BA058 for Osteoporosis -- more

March 19, 2007
ACADIA Announces Positive Results From ACP-103 Phase II Schizophrenia Co-Therapy Trial -- more

March 15, 2007
ExonHit Identifies a Panel of Genes to Diagnose, From Blood, Alzheimer's Disease -- more

March 14, 2007
Tragara Pharmaceuticals, Inc. Announces Corporate Launch and Series A Financing -- more

March 14, 2007
Critical Therapeutics and DEY, L.P. Enter into Co-Promotion Agreement for Respiratory Care Products -- more

March 13, 2007
Memory Pharmaceuticals Commences Phase 2a Trial of MEM 3454 in Alzheimer's Disease -- more

March 6, 2007
Avalon Pharmaceuticals and Merck & Co., Inc. Establish a Drug Discovery, Development and Commercialization Collaboration -- more

March 5, 2007
Lilly Announces Acquisition of Hypnion -- more

March 5, 2007
FlowMedica: Targeted Renal Therapy for Patients at Risk for Contrast-Induced Nephropathy -- more

March 5, 2007
Asterand Offers Researchers Internet Access to RNA to Speed Drug Discovery -- more

March 2, 2007
Santhera Reports Successful 2006 -- more

March 1, 2007
Santhera Board Proposes the Election of Klaus Schollmeier to the Company's Board -- more

February 20, 2007
Cyberkinetics Files to Market Andara(TM) OFS(TM) Therapy for Acute Spinal Cord Injury under Humanitarian Device Exemption -- more

February 13, 2007
Critical Therapeutics Announces Beckman Coulter Exercises Option to Continue HMGB1 Diagnostic Development -- more

February 13, 2007
Elixir Pharmaceuticals and Siena Biotech S.p.A. Enter Agreement to Evaluate SIRT1 Inhibitors in Huntington's Disease -- more

February 13, 2007
Dynogen Reports Positive Results in Phase 2 IBS-c Study -- more

January 31, 2007
Santhera Intends Early Filing in Europe for SNT-MC17/idebenone in Friedreich's Ataxia -- more

January 31, 2007
Santhera Updates Development Strategy for SNT-MC17/idebenone in Friedreich's Ataxia in the US -- more

January 30, 2007
Critical Therapeutics Licenses Rights for Vagus Nerve Stimulation Device to Innovative Metabolics -- more

January 19, 2007
Claros Diagnostics Secures $7.8 Million Series A Financing to Develop Handheld Point-of-care Diagnostics Platform -- more

January 17, 2007
Elixir Pharmaceuticals Presents New Data Highlighting Ghrelin Inhibition as a Potential Method for Regulating Metabolism and Treating Diabetes -- more

January 16, 2007
Trubion Announces Completion of Enrollment and Dosing of Patients in Phase IIb Clinical Trial of TRU-015 for the Treatment of Rheumatoid Arthritis -- more

January 8, 2007
Solexa Genome Analysis System Achieves 1G Performance Milestone -- more

January 4, 2007
AVEO acquires Clinical Stage Anti-Cancer Compound from Kirin -- more

December 15, 2006
Cohesive Technologies Inc.: Thermo Fisher Scientific Acquires Provider of Sample Extraction and Liquid Chromatography -- more

December 15, 2006
Critical Therapeutics Announces NIH-Sponsored Study to Investigate the Efficacy Of ZYFLO(R) In Patients with Acute Exacerbations Of COPD -- more

December 12, 2006
Abbott and Enanta Form Worldwide Alliance to Develop and Commercialize HCV Protease Inhibitors -- more

December 11, 2006
Xanthus Presents Preclinical Data Demonstrating Potent Symadex Activity in Leukemia Cells -- more

December 11, 2006
Memory Pharmaceuticals Announces Release of Clinical Hold on MEM 3454 -- more

December 4, 2006
Xanthus Completes Enrollment of Phase 2 Trial of Xanafide for the Treatment of Secondary AML -- more

December 4, 2006
Astex Therapeutics Appoints John Aston Chief Financial Officer -- more

November 30, 2006
Xanthus Secures $25 Million to Advance Development of Its Pipeline -- more

November 30, 2006
Santhera and Biozentrum Basel participate in the pan-European TREAT-NMD initiative to advance the treatment of rare neuro-muscular diseases -- more

November 29, 2006
ImpactRx, Inc. Names Altus President and Chief Executive Officer -- more

November 27, 2006
Memory Pharmaceuticals Completes Enrollment for MEM 1003 Bipolar Trial -- more

November 20, 2006
Memory Pharmaceuticals Earns Milestone Payment for Phase 2a Trial of MEM 1003 in Bipolar Disorder -- more

November 15, 2006
The Leukemia & Lymphoma Society and Ensemble Discovery Corp. Initiate Research Program to Apply New Technology to Better Diagnose Blood Cancers -- more

November 13, 2006
NIH and Santhera Announce Positive Results of Study with SNT-MC17/idebenone in Friedreich's Ataxia -- more

November 8, 2006
Solstice Neurosciences Raises $85 Million in Private Financing -- more

November 7, 2006
Mitralign Shines at TCT 2006; Performs Live Case & Reveals Clinical Strategy -- more

November 1, 2006
Pathway Medical Closes $25 Million in Funding -- more

November 1, 2006
Critical Therapeutics Announces Closing of $20.0 Million Registered Direct Offering -- more

October 31, 2006
Memory Pharmaceuticals to Receive $2 Million Milestone from Roche Related to MEM 3454 -- more

October 30, 2006
Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc. -- more

October 27, 2006
Critical Therapeutics Outlines New Business Strategy Focusing on Controlled-Release and Intravenous Formulations of Zileuton -- more

October 27, 2006
Critical Therapeutics to Sell 7.5 Million Shares of Registered Common Stock and Warrants to Purchase 3.7 Million Shares of Common Stock -- more

October 25, 2006
VaxInnate Secures $40 Million Series C Financing -- more

October 24, 2006
Asterand Isolates New Approach to Arthritis Research -- more

October 24, 2006
Alantos Pharmaceuticals and Servier Form Collaboration -- more

October 23, 2006
AVEO Pharmaceuticals Initiates Clinical Development of AV-412 in Cancer Patients with Advanced Solid Tumors -- more

October 23, 2006
VaxInnate Reports Promising Results for Novel Influenza Vaccine Candidates -- more

October 23, 2006
BrainCells and Organon to Collaborate in Discovery and Development of CNS Drugs -- more

October 19, 2006
ExonHit to Identify a Blood Diagnostic for Atherosclerosis -- more

October 18, 2006
Cyberkinetics Enters into Definitive Agreements for $10.0 Million Private Placement -- more

October 18, 2006
Solexa Announces Sequencing of a Human X-Chromosome -- more

October 17, 2006
Critical Therapeutics Announces Acceptance of Controlled-Release Zileuton New Drug Application for Review by FDA -- more

October 3, 2006
Xanthus Pharmaceuticals Expands Oncology Pipeline with Late-Stage Oral Fludarabine from Schering AG -- more

October 2, 2006
Biopharmaceutical Firm Trubion Plans 4 Million IPO Shares -- more

October 2, 2006
Technology behind Sirna Therapeutics subject of the 2006 Nobel Prize for Physiology and Medicine -- more

September 28, 2006
Memory Pharmaceuticals Achieves Milestone in PDE10 Collaboration With Amgen -- more

September 28, 2006
Xanthus' Symadex Can Reverse Disease in Preclinical Multiple Sclerosis Animal Model -- more

September 28, 2006
AVEO and XOMA Enter Into Supply Agreement for AVEO's Novel Anti-HGF Antibody -- more

September 25, 2006
ACADIA Pharmaceuticals Announces Accelerated Timing of ACP-103 Phase II Trial in Patients with Schizophrenia -- more

September 22, 2006
Santhera Appoints MJ Roach as Vice President Marketing and Sales -- more

September 19, 2006
Kurt H. Kruger Joins Cyberkinetics as Chief Financial Officer -- more

September 19, 2006
ExonHit Therapeutics Extends Strategic Alliance with Allergan -- more

September 15, 2006
Santhera Appoints New Board Directors -- more

September 14, 2006
Xanthus Presents In Vitro Data Demonstrating that Symadex Is a Potent and Selective Inhibitor of FLT3 -- more

September 13, 2006
Dynogen Initiates Phase 1b Trial of DDP733 in Gastroesophageal Reflux Disease (GERD) ' New Approach for Treating Nighttime Heartburn -- more

September 12, 2006
Radius & Karo Bio Announce Licensing Agreement for Novel SARM Compounds -- more

September 6, 2006
FDA Grants Humanitarian Use Device Designation to Cyberkinetics' Andara(TM) OFS Device for Acute Spinal Cord Injuries; Designation Marks Critical Regulatory Step Toward Commercialization -- more

September 6, 2006
Xanthus Pharmaceuticals Licenses Novel Cancer Targeting Agents From Schering AG, Berlin -- more

September 5, 2006
Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 1003 in Bipolar Disorder -- more

September 5, 2006
Santhera and Juvantia to Collaborate on Development of Phase II Product for Dyskinesia in Parkinson's Disease -- more

August 31, 2006
Exelixis Files IND Application for XL228 -- more

August 31, 2006
Solexa Appoints Blaine Bowman and Roy Whitfield to Board of Directors -- more

August 23, 2006
Critical Therapeutics Announces Results of Phase I/II Trial of Intravenous Formulation of Zileuton -- more

August 10, 2006
Sirna Therapeutics Reports Final Results from Phase 1 Study on Its RNAi-Based Therapeutic for Age-Related Macular Degeneration -- more

August 10, 2006
BrainCells In-Licenses Clinical-Stage CNS Compound From Mitsubishi Pharma -- more

August 7, 2006
Radius Licenses Worldwide Exclusive Rights to Estrogen Receptor-Beta Agonists -- more

August 3, 2006
Solexa Appoints Joseph Whitters to Board of Directors -- more

July 31, 2006
Critical Therapeutics Submits New Drug Application for Controlled-Release Formulation of Zileuton To FDA -- more

July 17, 2006
Memory Pharmaceuticals Achieves Milestone Under Nicotinic Alpha-7 Collaboration With Roche -- more

July 13, 2006
Cyberkinetics' Neural Sensing Technology Highlighted in Second Study Published in Nature -- more

July 12, 2006
MicroMed Announces Hiring of Alan Totah as Senior Vice President of Regulatory Affairs and Quality Systems -- more

July 11, 2006
Solexa Announces Initial System Shipments; Early Access Program Underway with Leading Genome Institutes -- more

July 10, 2006
Ceres Announces Genomics Milestone in Energy Crop Enhancement Program -- more

July 10, 2006
PowderMed to Conduct Clinical Trial of its Novel DNA-Based H5N1 (Avian) Influenza Vaccine in London -- more

July 6, 2006
Asterand signs partnership to supply drug discovery services to Japan -- more

July 3, 2006
Solexa Joins Russell 3000 Index -- more

June 30, 2006
Asterand Announces Collaboration with Rubicon Genomics to Develop New Cancer Diagnostic Tests -- more

June 29, 2006
Cyberkinetics Reports Preliminary BrainGate Data from Non-Speaking, Paralyzed Participant at ASIA Meeting in Boston -- more

June 29, 2006
Radius Announces Licensing Agreement to Develop and Commercialize Eisai SERMs -- more

June 23, 2006
European Patent Office Significantly Limits Scope of Kreutzer-Limmer RNAi Patent Claim -- more

June 20, 2006
Rib-X Pharmaceuticals Raises $50 Million in Series C Financing -- more

June 19, 2006
MicroMed Announces Closing of $15.425 Million Financing -- more

June 7, 2006
Ceres and Noble Foundation Establish Collaboration for New Energy Crops -- more

June 5, 2006
Cyberkinetics Reports First Data from Non-Speaking, Paralyzed Participant in Ongoing Study of BrainGate Neural Interface System - Expanded Evidence of Brain Computer Interface Utility Presented at ASSFN Meeting in Boston -- more

June 5, 2006
Xanthus Presents Symadex Phase 1 Results at American Society of Clinical Oncology Meeting -- more

June 5, 2006
Xanthus Meets Milestone in Phase 2 Clinical Study of Xanafide for Treatment of Secondary AML -- more

June 2, 2006
Trubion Files for Initial Public Offering -- more

June 1, 2006
Rib-X Pharmaceuticals and Wakunaga Pharmaceutical Company Announce License Agreement for Quinolone Antibiotic -- more

June 1, 2006
Cyberkinetics and Minnetronix Finalize Design and Manufacturing Agreement for the Andara OFS Device to Treat Acute Spinal Cord Injuries -- more

May 31, 2006
UMass Medical School Partners with PowderMed to Test Potential Avian Flu Vaccine -- more

May 31, 2006
Study in the Journal "Vaccine" Reports Positive Results of DNA-Based Flu Vaccine in Humans -- more

May 24, 2006
Sirna Therapeutics Announces Pricing of Common Stock Offering -- more

May 22, 2006
Xanthus Pharmaceuticals Appoints John Lister-James, Ph.D. as Vice President, Development -- more

May 16, 2006
Solexa Added to NASDAQ Biotech Index -- more

May 10, 2006
Sirna Therapeutics Licenses Worldwide Exclusive Rights to microRNA Technology from University of Massachusetts Medical School -- more

May 4, 2006
Sirna Therapeutics Announces Programs in Strategic Research Alliance With GlaxoSmithKline -- more

May 2, 2006
Critical Therapeutics on Target to Submit NDA for Zileuton Controlled-Release Tablets in Third Quarter 2006 -- more

April 24, 2006
CardioFocus Completes Series C Financing; H.I.G. Ventures and KBL Healthcare Ventures Lead $21.5 Million Round for Developer of First Endoscopically-Guided Catheter Ablation System to Treat Atrial Fibrillation -- more

April 17, 2006
Asterand Announces New Test to Reduce Risks in Human Drug Trials -- more

April 12, 2006
Targacept Announces Pricing of Its Initial Public Offering -- more

April 12, 2006
Radius Appoints Louis O'Dea Senior Vice President and Chief Medical Officer -- more

April 10, 2006
HydroCision receives 2006 'Medical Design Excellence Award' (MDEA) for its SpineJet' MicroResector -- more

April 3, 2006
GlaxoSmithKline and Sirna Therapeutics Announce Major Alliance in RNAi-Based Therapeutics for Respiratory Disease -- more

March 29, 2006
PowderMed's Therapeutic DNA Vaccine for Chronic Hepatitis B Enters Phase 1 Clinical Trials in Patients -- more

March 29, 2006
ExonHit and BioM'rieux reach an important research milestone in the molecular detection of breast cancer from blood samples -- more

March 27, 2006
Elixir Pharmaceuticals Acquires Late-Stage Product for the Treatment of Type II Diabetes -- more

March 23, 2006
ACADIA Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease -- more

March 14, 2006
Dynogen Initiates Phase II Trial of DDP225 for Treatment of Chronic Functional Vomiting -- more

March 14, 2006
Sirna Therapeutics Announces Its Scientific Advisory Board -- more

March 10, 2006
X-Cell Begins Trial of its Ethos DES Product Using Estradiol -- more

March 8, 2006
X-Cell Medical Initiates Enrollment for ETHOS II Clinical Trial of Estradiol Eluting Stent -- more

March 1, 2006
R. Scott Greer Named Chairman of the Board of Sirna Therapeutics and Lutz Lingnau Appointed as New Board Member -- more

March 1, 2006
Inverness Medical Innovations Acquires CLONDIAG Chip Technologies -- more

February 28, 2006
Memory Pharmaceuticals Expands Roche Nicotinic Alpha-7 Alliance -- more

February 23, 2006
X-Cell Medical: Putting Safety First -- more

February 21, 2006
Solexa Transfers Listing to The Nasdaq National Market -- more

February 17, 2006
ExonHit Therapeutics Will Begin Continuous Trading on Alternext -- more

February 15, 2006
Critical Therapeutics Completes Dosing of First Patient in Clinical Trial of Intravenous Zileuton -- more

February 9, 2006
ExonHit SpliceArray Service Welcomes Its 50th Commercial Contract -- more

February 6, 2006
Dr. Derek M. Winstanly Joins Xanthus Life Sciences' Board of Directors -- more

January 24, 2006
Astex grants Cytochrome P450 license to Pfizer -- more

January 20, 2006
Solexa Completes Second Closing of $65 Million Private Equity Financing -- more

January 19, 2006
Enanta Pharmaceuticals Announces Initiation of Phase 2 Studies in North America on First-in-Class Antibiotic EDP-420 for the Treatment of Community Acquired Pneumonia -- more

January 17, 2006
Targacept Files for Initial Public Offering -- more

January 17, 2006
Xanthus Initiates Phase 2 Clinical Trial with Symadex in Patients with Metastatic Colorectal Cancer -- more

January 9, 2006
Avalon Pharmaceuticals Initiates AVN944 Phase I Clinical Trial in Cancer Patients -- more

January 5, 2006
AVEO Pharmaceuticals Acquires Rights to Novel Anti-Cancer Compound from Mitsubishi Pharma Corporation -- more

January 3, 2006
Wyeth Announces Strategic Collaboration with Trubion Pharmaceuticals -- more

January 3, 2006
Santhera Announces Management Buy-Out of the Graffinity Drug Discovery Technology Business -- more

January 3, 2006
Xanthus Initiates Phase 2 Clinical Trial with Symadex in Women With Metastatic Breast Cancer -- more

December 28, 2005
Targacept and AstraZeneca Announce Global License and Research Collaboration Agreement -- more

December 22, 2005
Richard W. Dugan Joins Xanthus Life Sciences' Board of Directors -- more

December 22, 2005
Inverness Medical Innovations Receives FDA Clearance for Sale of its Albumin Cobalt Binding (ACB(R)) Test for Detection of Ischemia Modified Albumin (IMA(R)) on Roche Chemistry Analyzers -- more

December 22, 2005
Exelixis and Wyeth Sign License Agreement Related to Novel Treatments for Metabolic and Liver Diseases -- more

December 21, 2005
Sirna Therapeutics Selects Development Candidate for Its Hepatitis C Antiviral Program -- more

December 20, 2005
Critical Therapeutics Initiates Pharmacokinetic Studies of Zileuton Controlled-Release Tablets; Data to support New Drug Application for twice-a-day formulation of zileuton -- more

December 20, 2005
Santhera Raises CHF 25 million ('16 million) Via a Further Closing of its 2005 B Financing Round -- more

December 20, 2005
Enanta Pharmaceuticals Achieves Milestone in Alliance with Shionogi & Co., Ltd. -- more

December 20, 2005
Memory Pharmaceuticals Announces Agreement with the Stanley Medical Research Institute for the Development of MEM 1003 for Bipolar Disorder -- more

December 20, 2005
Memory Pharmaceuticals Announces Preliminary Results from Safety and Tolerability Study for MEM 1003 in Alzheimer's Patients -- more

December 20, 2005
Exelixis Initiates Phase II Clinical Program for XL999 -- more

December 19, 2005
Critical Therapeutics to Initiate Clinical Study of Intravenous Formulation of Zileuton; Phase I/II Asthma Study Scheduled to Begin in the First Quarter of 2006 -- more

December 15, 2005
Santhera Starts European Phase III Study with its Lead Compound SNT-MC17 (idebenone) in Friedrich's Ataxia -- more

December 13, 2005
Radius Announces Licensing Agreement for Ipsen Osteoporosis Proprietary Molecule BA058 -- more

December 12, 2005
Solexa Introduces the Solexa Genome Analysis System -- more

December 8, 2005
Critical Therapeutics Achieves Collaboration Milestone in HMGB1 Program; Demonstrates Efficacy of HMGB1 Antibodies in Preclinical Models of Inflammation -- more

December 6, 2005
Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Develop Novel Cardiovascular Disease Treatments -- more

December 6, 2005
Astex Announces New Licensing and Drug Discovery Alliance to Develop Novel Cell Cycle Cancer Drugs -- more

December 1, 2005
NBC's Today Show Features Cyberkinetics' BrainGate System: In Clinical Trials to 'Turn Thought into Action'; Clinical Trial Participant with Quadriplegia Uses His Own Thoughts to Control a Computer and a Prosthetic Hand -- more

November 24, 2005
New Paper Highlights ExonHit's Novel Approach for the Treatment of Alzheimer's Disease -- more

November 21, 2005
X-Cell Medical Completes Enrollment for Clinical Trial of ETHOS I Estradiol Eluting Stent -- more

November 21, 2005
Solexa Announces Agreement for $65 Million Private Placement -- more

November 21, 2005
Sirna Therapeutics to Join the NASDAQ Biotechnology Index -- more

November 15, 2005
Xanthus Life Sciences Appoints J. Kris Piper as Vice President of Regulatory Affairs and Quality Assurance -- more

November 14, 2005
BioProcessors: Having Identified Rapid, Early Process Development as Critical to the Success of Novo Nordisk's Biologics Programs, Company Chooses SimCell' MicroBioreactor System For High-Throughput Mammalian Cell Culture Process Development -- more

November 14, 2005
Elixir: Want to Live Forever? -- more

November 8, 2005
FlowMedica Inc., Completes $15 Million Series D Financing -- more

November 7, 2005
Critical Therapeutics' Study Suggests Steroid-Sparing Effect of ZYFLO(R) in Patients with Severe Asthma -- more

November 4, 2005
Memory Pharmaceuticals Commences Phase 2a Trial of MEM 1003 in Alzheimer's Disease -- more

November 3, 2005
Santhera and the NIH Collaborate to Evaluate SNT-MC17 in Friedreich's Ataxia -- more

November 2, 2005
Critical Therapeutics' ZYFLO(R) Reduces Need for Rescue Medication and Significantly Improves Lung Function in Severe Asthma Patients -- more

November 2, 2005
AVEO Pharmaceuticals and Merck Sign Collaboration for Clinical Drug Response Prediction -- more

October 24, 2005
Cardiome Acquires Artesian Therapeutics -- more

October 20, 2005
Xanthus Initiates a Phase 2 Study Of Xanafide in Combination with ara-C for Treatment Of Secondary AML -- more

October 19, 2005
Santhera Targets New Indication with its Lead Compound -- more

October 18, 2005
BrainCells, Inc. Appoints James A. Schoeneck Chief Executive Officer -- more

October 17, 2005
Memory Pharmaceuticals Announces Collaboration to Develop PDE10 Inhibitors for Central Nervous System Disorders with Amgen -- more

October 17, 2005
Dynogen Initates Phase II Trial of DDP225 for Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome -- more

October 12, 2005
Cellzome and Santhera's business unit, Graffinity, awarded Euro 2.2 million grant from German Government -- more

October 10, 2005
Critical Therapeutics Announces Commercial Launch of ZYFLO(R); Studies Showed ZYFLO Reduced the Need for Rescue Medications and Improved Asthma Symptoms -- more

September 30, 2005
John P. Donoghue Honored for Cyberkinetics' Groundbreaking BrainGate(TM) Brain-Computer Interface at the 'Popular Mechanics 2005 Breakthrough Awards -- more

September 30, 2005
Avalon Pharmaceuticals Announces the Activation of IND for AVN944 for the Treatment of Cancer -- more

September 29, 2005
Avalon Pharmaceuticals Announces Pricing of Initial Public Offering -- more

September 29, 2005
Xanthus Life Sciences Awarded Grant from NCI to Develop Technology for Personalized Dosing of Anticancer Drugs -- more

September 29, 2005
Sirna Therapeutics and Allergan Enter Into Strategic Ophthalmology Alliance -- more

September 28, 2005
Critical Therapeutics Announces FDA Approval of ZYFLO(R) for the Prevention and Chronic Treatment of Asthma; Oral Drug Blocks the Production of Mediators That Can Trigger Asthma Symptoms -- more

September 28, 2005
Dynogen initiates Phase II trial of DDP733 for treatment of patients with constipation-predominant irritable bowel syndrome -- more

September 27, 2005
Cyberkinetics Announces $11.4 Million Private Financing -- more

September 26, 2005
Memory Pharmaceuticals Completes Safety and Tolerability Study of MEM 1003; Preparing to Commence Dosing Patients in Phase 2a Trial -- more

September 23, 2005
Xanthus Life Sciences Appoints John A. McCarthy, Jr. as Senior Vice President and Chief Financial Officer -- more

September 21, 2005
Memory Pharmaceuticals Announces $31 Million Financing -- more

September 19, 2005
Merger of Pharmagene Plc and Asterand, Inc. to Form a Leading Company in Human Tissue Supply and Human Tissue Based Research Services -- more

September 13, 2005
Avalon Pharmaceuticals Announces Small Molecule Drug Discovery Program -- more

September 13, 2005
ACADIA Pharmaceuticals Announces Election of Michael T. Borer to Board of Directors -- more

September 7, 2005
Avalon Pharmaceuticals, Inc. Announces Filing of IND for AVN944 for the Treatment of Cancer -- more

September 6, 2005
Solexa and Collaborating Scientists Illuminate the Small RNA Component of the Transcriptome; Research Published in ''Science'' Demonstrates the Value of High-Throughput Sequencing in Small RNA Analysis -- more

August 31, 2005
Astex announces new drug discovery collaboration with Boehringer Ingelheim -- more

August 29, 2005
Cardiome Announces LOI to Acquire Artesian Therapeutics -- more

August 24, 2005
Dennis H. Langer Appointed to Sirna Therapeutics Board of Directors -- more

August 22, 2005
ALS Patients Offered Access to Cyberkinetics' BrainGate(TM) System in New Pilot Study at Massachusetts General Hospital -- more

August 22, 2005
World Renowned Geneticist David Bentley, D.Phil., Joins Solexa as Chief Scientist -- more

August 17, 2005
X-Cell Medical Commences Randomized Clinical Trial of Estradiol Eluting Stent -- more

August 17, 2005
Biovitrum and Santhera sign an exclusive license and collaboration agreement for the development of DPP-IV inhibitors for the treatment of type 2 diabetes and other metabolic diseases -- more

August 3, 2005
Santhera and Takeda Establish Collaboration to Develop and Market Idebenone (SNT-MC17) in Neuromuscular Disease -- more

August 1, 2005
PowderMed Manufactures a Vaccine Against HSN1 (Avian Influenza) for Clinical Development -- more

July 27, 2005
AstraZeneca and Astex announce new anti-cancer drug discovery alliance -- more

July 26, 2005
BioSource Signs Definitive Merger Agreement and Reports Record Second Quarter Sales -- more

July 25, 2005
Exelixis Initiates Phase I Clinical Trial for Anticancer Compound XL820 -- more

July 25, 2005
First Demonstration of Systemic siRNA Efficacy at Therapeutically Relevant Doses is Published by Sirna Therapeutics -- more

July 14, 2005
BrainCells Inc. Announces $17.7 Million Series A Financing -- more

July 12, 2005
BioProcessors' SimCell' Platform Demonstrates Potential to Increase Amgen's Cell Culture Experiment Capacity -- more

July 12, 2005
Solexa Completes $24 Million Private Equity Financing -- more

July 7, 2005
Sirna Therapeutics Completes Initial Closing of a $28 Million Financing -- more

July 5, 2005
Elixir Pharmaceuticals: Nature Publication Reports Key Links Between Mechanisms of Aging and Metabolic Disorders -- more

July 5, 2005
James B. Tananbaum, M.D. Joins Critical Therapeutics' Board of Directors -- more

June 28, 2005
Cambrios Names Xina Quan as First Vice President of Research & Development -- more

June 27, 2005
US Tissue Bank, Asterand, Expands Service to Europe -- more

June 27, 2005
Astex Announces IND Approval for Novel Cancer Drug AT7519 -- more

June 22, 2005
ACADIA Pharmaceuticals Announces Encouraging Interim Results From Ongoing Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease -- more

June 21, 2005
Critical Therapeutics Announces Closing of $54.5 Million Private Placement -- more

June 20, 2005
MedImmune And Avalon Pharmaceuticals Announce Collaboration to Discover Small Molecule Therapeutic Drugs for Inflammatory Diseases -- more

June 14, 2005
Exelixis Files IND Application for Anticancer Compound XL184 -- more

June 13, 2005
Sirna Therapeutics Announces Collaboration with Massachusetts General Hospital to Evaluate Potential of siRNAs in Hearing Restoration -- more

June 13, 2005
Exelixis Announces Transaction to Fund Clinical Development for XL647, XL999 and XL784 -- more

June 13, 2005
Exelixis and Helsinn Sign Agreement for XL119 (becatecarin) -- more

June 8, 2005
Detroit's Asterand voted best place to work for scientists -- more

June 7, 2005
Sirna Therapeutics Publishes Hepatitis B Virus Data in June 2005 Issue of Hepatology -- more

June 7, 2005
Critical Therapeutics Announces $54.5 Million Private Placement -- more

May 23, 2005
Two Studies Support Efficacy of Critical Therapeutics' ZYFLO in Moderate to Severe Asthma Patients; Data Presented at the American Thoracic Society's 2005 International Conference -- more

May 23, 2005
Astex announces Clinical Trial Authorization for novel cancer drug AT7519 and plans for two further new drug filings in the next nine months -- more

May 20, 2005
Detroit Company, Asterand, Named High Technology Company of the Year -- more

May 19, 2005
Chiron and Enanta Announce Agreement for Development and Commercialization of HCV Therapeutics -- more

May 17, 2005
Xanthus Presents at ASCO: Phase 1 Data Shows Significant Activity of Amonafide in Combination With ara-C for Treatment of Poor Risk AML -- more

May 9, 2005
Exelixis Achieves $35 Million in Milestones From GSK -- more

May 7, 2005
Santhera Presents at the International Congress of Myology -- more

May 4, 2005
Xanthus Names Robert L. Capizzi, M.D., F.A.C.P. Chief Medical Officer -- more

May 4, 2005
Avalon Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering -- more

May 4, 2005
Sirna Therapeutics Announces Results From Interim Analysis of Phase 1 Single Dose Trial With Sirna-027 in Patients With Age-Related Macular Degeneration -- more

May 3, 2005
Roche Makes Initial Payment of $2 Million to Retain Option to License Memory Pharmaceuticals' MEM 3454 -- more

May 3, 2005
Santhera Announces the Appointment of Barbara A. Heller as Chief Financial Officer -- more

April 29, 2005
Asterand: Local Small Business Honored as One of '50 Companies to Watch in Michigan' -- more

April 28, 2005
Elixir Pharmaceuticals Licenses Novel Growth Hormone Secretagogue Compound from Bristol-Myers Squibb for Treatment of Metabolic Disorders -- more

April 27, 2005
ABIOMED Announces Execution of a Definitive Agreement to Acquire Impella CardioSystems AG -- more

April 25, 2005
ExonHit Therapeutics Granted New Patent; Becomes Key Player in the Microarray Market -- more

April 25, 2005
Exelixis Files IND Application for Novel Anticancer Compound XL820 -- more

April 18, 2005
Xanthus Presents Symadex Gene Expression Study at AACR: Preclinical Study Hints at Potential for Multiple Sclerosis -- more

April 15, 2005
ACADIA Pharmaceuticals Announces $36 Million Financing -- more

April 14, 2005
Boston Scientific Corporation and Rubicon Medical Corporation Amend Agreements and Boston Scientific Exercises Option to Acquire Control of Rubicon -- more

April 4, 2005
Reviving an Old Drug: Critical Therapeutics relaunches an asthma drug with the help of Rhodia manufacturing -- more

April 4, 2005
Ensemble Discovery Names Richard F. Begley as CEO; Begley Leverages Knowledge of Chemistry, Biology and Engineering -- more

April 4, 2005
Cyberkinetics Receives Neuroport 510K Clearance; Acute Neural Monitor is Company's First Commercial Clinical Product -- more

April 4, 2005
Cyberkinetics Gives Update on BrainGate Clinical Trial -- more

April 1, 2005
Critical Therapeutics Submits Supplemental New Drug Application to FDA for ZYFLO -- more

March 31, 2005
Cyberkinetics Announces Results for Fiscal Year Ended December 31, 2004; Product Development and Clinical Progress Highlight Year -- more

March 31, 2005
Brain chip reads man's thoughts -- more

March 23, 2005
Sirna Therapeutics Appoints Dr. Keith Yamamoto to Chairperson of SAB -- more

March 17, 2005
Exelixis Initiates Phase I Trial for Anticancer Compound XL880 -- more

March 14, 2005
Critical Therapeutics Initiates Open-Label Study of ZYFLO; Study Provides Certain Patients Access to ZYFLO Prior to Commercial Availability -- more

March 14, 2005
Enanta Pharmaceuticals Achieves Milestone in Collaboration with Shionogi & Co., Ltd., as Phase 1 Studies Initiate in Japan on EP-013420, a First-In-Class Bridged Bicyclic Ketolide Antibiotic -- more

March 10, 2005
Alantos Pharmaceuticals Raises $20 Million in Private Placement -- more

March 10, 2005
Solexa Completes First Full Genome Sequence with Cluster-SBS Technology -- more

March 1, 2005
Lynx Stockholders Overwhelmingly Approve Solexa-Lynx Business Combination -- more

March 1, 2005
GENPATH PHARMACEUTICALS BECOMES AVEO PHARMACEUTICALS -- more

February 24, 2005
Six-Month Results of Cyberkinetics' BrainGate Neural Interface System Pilot Study Presented at AAP Meeting -- more

February 24, 2005
Santhera Reaches Milestone in Serono Drug Discovery Collaboration -- more

February 22, 2005
Sirna Therapeutics Granted Two Key Patents on Its RNA Interference Technology -- more

February 20, 2005
Rolf Stahel Appointed as Chairman of Powdermed -- more

February 15, 2005
Critical Therapeutics Initiates Phase II Clinical Study of CTI-01 -- more

February 14, 2005
Sosei Co. Ltd: SOT-107 Granted Orphan Designation in Japan -- more

February 14, 2005
Astex achieves drug discovery milestone with Boehringer Ingelheim -- more

February 9, 2005
Rhodia Pharma Solutions and Critical Therapeutics Sign Long-Term Supply Agreement for Zileuton -- more

February 1, 2005
Dr Peter Ringrose joins Astex Board -- more

January 24, 2005
Astex granted patent covering use of crystal structure of human cytochrome P450 3A4, the most important drug metabolising enzyme in man -- more

January 21, 2005
Xantos Biomedicine AG Successfully Advances a Development Project for Roche -- more

January 14, 2005
Scion Pharmaceuticals Announces the Appointment of Dr. Barry A. Berkowitz as President and Chief Executive Officer -- more

January 11, 2005
Sirna Therapeutics and Targeted Genetics Form Huntington's Disease Collaboration -- more

January 11, 2005
ACADIA Pharmaceuticals Announces Partnership With Sepracor -- more

January 10, 2005
Trubion Announces Initiation of First Phase I Study in Rheumatoid Arthritis -- more

January 10, 2005
Exelixis Amends Collaboration With GlaxoSmithKline -- more

January 6, 2005
Sirna Therapeutics Launches Program to Treat Asthma With RNAi Technology -- more

January 6, 2005
Sirna Therapeutics Launches Program to Treat Diabetes with RNAi Technology -- more

December 17, 2004
Santhera Pharmaceuticals AG Completes First Round of Financing Raising Euro 14 Million -- more

December 16, 2004
Elixir Extends IP Surrounding SirT Deacetylases with Exclusive License to SirT2 and SirT3 Patents from University of California -- more

December 9, 2004
World Economic Forum Selects Memory Pharmaceuticals as 2005 Technology Pioneer -- more

December 8, 2004
Red Herring Selects Avalon Pharmaceuticals for Prestigious Red Herring Top 100 Innovators Award -- more

December 8, 2004
Sirna Therapeutics Launches Dermatology Division Targeting Permanent Hair Removal With siRNAs -- more

December 7, 2004
Spaulding Rehabilitation Hospital Joins Cyberkinetics' BrainGate Neural Interface System Pilot Study -- more

December 6, 2004
ZettaCore Named 2005 Technology Pioneer by World Economic Forum -- more

December 6, 2004
Astex chosen by the World Economic Forum as a Technology Pioneer for 2005 -- more

December 2, 2004
DrugMax, Inc. Secures $17 Million Private Placement -- more

December 2, 2004
Astex Awarded The Sunday Times Microsoft Tech Track 100 Research and Development Award 2004 -- more

December 1, 2004
Japanese drug maker Kyorin Pharmaceutical Co. Agrees to Buy Unlisted ActivX Biosciences Inc. for $21 million. -- more

November 30, 2004
Santhera Pharmaceuticals Announces the Appointment of Pierre Vankan, Ph.D. as Vice President, Drug Development and Global Project Management -- more

November 23, 2004
Sirna Therapeutics Commences Phase I Clinical Trial for Age-Related Macular Degeneration at Cleveland Clinic -- more

November 17, 2004
Positive Outcome of Phase I DNA Influenza Study: PowderMed announces first clinical trial results -- more

November 15, 2004
FDA Approves superDimension/Bronchus -- more

November 15, 2004
DrugMax and Familymeds Complete Merger -- more

November 1, 2004
Sosei Announces the Launch of its US Company Targeting the Development of CNS Compounds. Deal with Mitsubishi Pharma Corporation Provides the Platform -- more

November 1, 2004
Bristol-Myers Squibb Medical Imaging and IMCOR Pharmaceutical Co. Enter into Cross-Licensing Agreement for Ultrasound Contrast Patents -- more

October 26, 2004
ACADIA Pharmaceuticals Earns Milestone on Advancement of Neuropathic Pain Drug -- more

October 25, 2004
Astex Achieves Drug Discovery Collaboration Success with Schering AG -- more

October 21, 2004
Clinical MicroArrays Announces $7.5 Million Series A Financing -- more

October 20, 2004
Sirna Therapeutics Announces RNAi Therapeutic Development Program to Address Huntington's Disease -- more

October 14, 2004
Xanthus Initiates Second Phase 1 Trial for Symadex to Study Daily Dosing in Patients with Solid Tumors -- more

October 14, 2004
Cyberkinetics' Chief Scientific Officer, John Donoghue, Ph.D., Receives Discover Magazine's Innovations Award for Neuroscience; Cited for Work on Brain-Computer Interface -- more

October 14, 2004
Critical Therapeutics Appoints Pharmaceutical Industry Veteran Robert Zeiger as Independent Director -- more

October 13, 2004
Critical Therapeutics Reports Successful Multiple-Dose Phase I Study of CTI-01 -- more

October 12, 2004
PowderMed Initiates a Phase I Clinical Trial for a Novel Therapeutic Herpes Simplex Type 2 (HSV 2) DNA Vaccine -- more

October 11, 2004
Astex Strengthens Management Team - Martin Buckland Joins as Senior Vice President, Business Development -- more

October 8, 2004
Initial Results of Cyberkinetics' BrainGate Neural Interface System Pilot Study Presented at AAPM&R Meeting -- more

October 7, 2004
Cyberkinetics Neurotechnology Systems, Inc. (OTCBB: TGRV) Completes Merger, Name Change and Reincorporates in Delaware -- more

October 7, 2004
Santhera Pharmaceuticals and Genzyme Enter Into Option and License Agreement for Discovery of Therapies for Muscle Diseases -- more

October 5, 2004
Critical Therapeutics to Begin Phase II Study of Zileuton for Moderate to Severe Acne; Efficacy and Safety Trial to be Conducted in up to 90 Patients -- more

October 5, 2004
ZettaCore Expands Management Team With Appointment of Chief Executive and Vice President -- more

October 5, 2004
Astex ranked top biotech company for the second year running in The Sunday Times Microsoft Tech Track 100 -- more

October 4, 2004
NuVios Names C. Richard Lyttle President & CEO -- more

September 28, 2004
Cambrios founder Angela Belcher wins MacArthur 'Genius' award -- more

September 28, 2004
Solexa & Lynx Merge to Create Future-Sequencing Powerhouse -- more

September 28, 2004
Solexa Announces Successful Closure of $14.4m financing -- more

September 16, 2004
Ludwig Institute for Cancer Research and PowderMed Initiate a Phase I Clinical Trial for a Novel Therapeutic Cancer Vaccine -- more

September 16, 2004
Illumina to Conduct Large-Scale Genotyping Study for North American Rheumatoid Arthritis Consortium -- more

September 15, 2004
ACADIA Clinical Study Shows ACP-103 Improves Clinical Profile of Antipsychotic Drug Treatment -- more

September 13, 2004
Elixir Pharmaceuticals Announces Issuance of Patent for "Methods of Identifying Lifespan Altering Agents" and Presentation of Data on Discovery of SIRT1 Inhibitors -- more

September 8, 2004
William K. Heiden Appointed CEO of Elixir Pharmaceuticals -- more

September 8, 2004
Graffinity Pharmaceuticals AG and MyoContract AG Merge to Form Santhera Pharmaceuticals AG -- more

September 7, 2004
Sirna Therapeutics' First IND Filing Applies Novel RNAi Therapy to the Treatment of Age-Related Macular Degeneration -- more

September 2, 2004
ACADIA Pharmaceuticals to Expand Scandinavian Chemistry Operations -- more

August 31, 2004
Enanta Pharmaceuticals Raises $20 Million in New Financing and Initiates Phase 1 Clinical Trial on EP-013420 -- more

August 27, 2004
Solexa Announces the Appointment of John West as New CEO -- more

August 16, 2004
Concentric Medical: FDA Clears First Device for Removing Blood Clots in Stroke Patients -- more

August 16, 2004
Sirna Therapeutics' Collaborator Publishes a Study on RNAi Technology Targeting Neurodegenerative Diseases -- more

August 12, 2004
Illumina To Perform Large-Scale Mouse Genotyping Study For The Wellcome Trust Centre -- more

August 11, 2004
Illumina Receives $1.2 Million Grant From The National Institutes Of Health -- more

August 9, 2004
Exelixis Appoints George Poste to Board of Directors -- more

August 3, 2004
Xanthus Receives Patent on Technology to Measure Gastric Emptying -- more

August 3, 2004
ACADIA Study Links ACP-104 (N-desmethylclozapine) to Improved Cognition in Schizophrenia Patients -- more

July 28, 2004
Cyberkinetics Named Among Top 15 Emerging Life Sciences Companies of 2004 -- more

July 28, 2004
Sirna Therapeutics & Archemix Form Exclusive Aptamer Manufacturing Alliance -- more

July 27, 2004
Enanta Pharmaceuticals and Shionogi & Co., Ltd. Sign Agreement for Development and Commercialization of the First-in-Class Bridged Bicyclic Ketolide Antibiotic EP-013420 in Japan and East Asian Countries -- more

July 20, 2004
Critical Therapeutics to Initiate Phase I Study of Anti-Inflammatory Compound, CTI-01 -- more

July 20, 2004
Genomas and Illumina Form Strategic Alliance on Physiogenomics of Metabolic Syndrome -- more

July 19, 2004
SciQuest Stockholders Approve Acquisition by Trinity Ventures -- more

July 16, 2004
Astex reveals structure of key drug metabolizing enzyme - cytochrome P450 3A4 - in Science -- more

July 14, 2004
Trubion Raises $32 Million in Series B Financing to Fund Advancement of Lead Product Candidates -- more

June 29, 2004
Cellomics and GE Healthcare Collaborate To Provide Faster and More Effective Cellular Screening Solutions -- more

June 29, 2004
Exelixis Files IND Application for Anticancer Compound XL999 -- more

June 29, 2004
ACADIA Pharmaceuticals Presents Favorable Results From Phase Ib/IIa Clinical Trial and PET Study of ACP-103 -- more

June 28, 2004
Nuvelo Announces the Completion of Its Phase 2 Alfimeprase Trial in Acute Peripheral Arterial Occlusion -- more

June 24, 2004
Cellomics, Inc. Announces Appointment of Business Development Executive -- more

June 23, 2004
Exelixis Initiates Phase 3 Clinical Trial of XL119 in Bile Duct Cancer -- more

June 22, 2004
Cellomics and GE Healthcare Sign License Agreements to Expand Availability of High Content Screening -- more

June 21, 2004
Scientists vote Detroit's Asterand 'best place to work.' -- more

June 17, 2004
ExonHit develops a new improved formulation of Ikomio' for ALS patients -- more

June 15, 2004
Sosei Initiates Phase I Clinical Trial of Oral Sou-001 -- more

June 15, 2004
Lexicon Genetics Appoints Gregory M. Landes, Ph.D. Vice President of Biotherapeutics -- more

June 8, 2004
Sirna Therapeutics Evaluating RNAi to Treat Huntington's Disease -- more

June 8, 2004
Astex extends research collaboration with Aventis -- more

June 7, 2004
Inverness Medical Innovations, Inc. Acquires Advantage Diagnostics Corporation -- more

June 7, 2004
Sirna Therapeutics Demonstrates Systemic Efficacy of siRNAs in Multiple Animal Models -- more

June 7, 2004
Corixa and GlaxoSmithKline announce results of two studies of BEXXAR following chemotherapy as first-line treatment of non-Hodgkin's lymphoma presented at ASCO -- more

June 5, 2004
Nuvelo Announces Preliminary Phase 2 Alfimeprase Results in Acute Peripheral Arterial Occlusion Trial Presented Today at the Vascular 2004 Annual Meeting -- more

June 3, 2004
Exelixis Initiates Phase 1 Trial for Anticancer Compound XL647 -- more

May 27, 2004
Critical Therapeutics, Inc. Announces Pricing of Initial Public Offering -- more

May 26 2004
ACADIA Pharmaceuticals Announces Initial Public Offering -- more

May 25, 2004
Xanthus Commences Phase I/II Clinical Trial for Xanafide Amonafide in Patients -- more

May 17, 2004
PowderMed Spins Out Of Chiron With $34.5 Million Series A -- more

May 17, 2004
PowderMed launched in spin out of powder injection DNA vaccine programmes from Chiron vaccines -- more

May 14, 2004
Targacept files for initial public offering -- more

April 20, 2004
Roche adopts Cellomics Store and EMC Centera for High Content Screening Solution -- more

April 19, 2004
Astex achieves second milestone in Alzheimer's drug discovery collaboration with AstraZeneca -- more

April 19, 2004
Dynogen Secures $50 million Series B Financing to Advance its Pipeline of Genitourinary and Gastrointestinal Development Programs -- more

April 14, 2004
Brain implant devices approved for trials -- more

April 6, 2004
Memory Pharmaceuticals Stock Up After Delayed IPO -- more

April 6, 2004
ActivX Biosciences Announces Agreement with Gilead Sciences for Protein Activity Profiling -- more

April 5, 2004
Memory Pharmaceuticals Corp. Announces Pricing of Initial Public Offering -- more

March 29, 2004
Exelixis Describes the Discovery of Novel Cancer Targets at AACR -- more

March 29, 2004
Check Point Software Completes Zone Labs Acquisition -- more

March 26, 2004
Texas Children's Hospital Implants First MicroMed/DeBakey Child Venticular Assist Device -- more

March 25, 2004
Lynx and Solexa Jointly Acquire DNA Technology Assets -- more

March 22, 2004
Astex, The Wellcome Trust, The Institute of Cancer Research and Cancer Research Technology announce major cancer drug discovery collaboration -- more

March 15, 2004
Exelixis Granted Orphan Drug Designation for Anticancer Agent XL119 -- more

March 9, 2004
Cyberkinetics: Brain Power -- more

March 9, 2004
Astex announces drug discovery alliance with Boehringer Ingelheim -- more

March 3, 2004
The First Minituarized Heart Pump for Children Approved -- more

February 27, 2004
Acadia Pharmaceuticals Inc. Files Registration Statement For Initial Public Offering -- more

February 23, 2004
Exelixis Publishes World's Most Comprehensive Collection of Functional Gene Knockouts in a Multicellular Organism -- more

February 20, 2004
Graffinity Pharmaceuticals Completes Euro 15 Million Series C Round of Financing -- more

February 19, 2004
Exelixis Files IND Application for Anticancer Agent XL647 -- more

February 18, 2004
Vaughn M. Kailian Joins Elixir Pharmaceuticals As Chairman of the Board -- more

February 6, 2004
Concentric Medical: Tiny corkscrew stops strokes in tests -- more

February 4, 2004
Avalon Pharmaceuticals Discovers Prostate Cancer
Biomarker -- more

January 27, 2004
Targacept Announces Addition of Errol De Souza, Ph.D. to its Board of Directors -- more

January 23, 2004
HydroCision Sells Advanced Business to
Smith & Nephew -- more

January 21, 2004
Hypnion Names Dr. Robert Michael Poole Chief
Medical Officer -- more

January 20, 2004
ZettaCore Closes $17.5 Million in Series B
Financing -- more

January 15, 2004
Avalon Pharmaceuticals Announces Appointment of
James H. Meade, Ph.D. to Vice President for Business Development and the Promotion of Paul E. Young, Ph.D. to
Vice President of Research -- more

January 14, 2004
Enanta Pharmaceuticals Secures $12 Million Financing Under New Management -- more

January 13, 2004
Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference -- more

January 12, 2004
Exelixis Appoints Chief Financial Officer -- more

January 9, 2004
Cellomics, Inc. announces completion of new financing and balance sheet restructuring -- more

January 8, 2004
ACADIA Pharmaceuticals Achieves Milestone as Allergan Advances Glaucoma Drug Candidate -- more

January 6, 2004
Dr. George M. Milne, Jr. Joins Rib-X Pharmaceuticals Board of Directors -- more

January 6, 2004
Accelerated Technologies Raises $32 Million To Advance Multiple Cardiovascular Device Opportunities -- more

January 5, 2004
Dynogen Pharmaceuticals, Inc. Enters Into Overactive Bladder Collaboration with Johnson & Johnson Pharmaceutical Research & Development -- more

December 22, 2003
Nancy S. Lurker Named Chief Exectuive Officer and President of ImpactRx -- more

December 09, 2003
ImpactRx Expands to Provide Decision Support on Dermatology Market -- more

November 17, 2003
Genpath Pharmaceuticals and Merck Enter into Potential $100 Million Deal for the Discovery of Novel Cancer Drugs -- more

December 12, 2003
Xanthus Life Sciences Secures $30.8 Million to Develop Its Personalized Anticancer Medicines and Names Dr. Richard T. Dean as Chief Executive Officer -- more

October 09, 2003
CTI Raises $56M in Series B; Asthma Product to
Benefit -- more

October 01, 2003
GenPath Pharmaceuticals Raises $42.7 Million
in Series B Funding -- more